Drugs / haploidentical CD34-selected cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00604201 | May 2008 → Oct 2016 | aplastic anemia, myelodysplastic syndrome | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | haploidentical CD34-selected cells | “haploidentical CD34-selected cells from a related donor” NCT00604201 ↗ |
| Modality | Cell therapy | “The haploidentical stem cell product will be T-cell depleted and enriched for CD34 plus cells using the Miltenyi CliniMacs system.” NCT00604201 ↗ |